Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress Oct 4, 2016
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer Sep 12, 2016
Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016 Sep 7, 2016
Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting Jun 6, 2016
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting May 23, 2016
Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update May 9, 2016
Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting Apr 20, 2016
